
Latest Search

Quote
Back Zoom + Zoom - | |
<Research>Guotai Junan Initiates Rating Buy on SINO BIOPHARM w/ TP HKD10
Recommend 31 Positive 38 Negative 13 |
|
![]() |
|
Guotai Junan has initiated coverage on SINO BIOPHARM (01177.HK) with a Buy rating and a target price of HKD10. Its 2025-27 EPS forecasts for the company were RMB0.293/ RMB0.259/ RMB0.283. While investment sentiment in China's healthcare sector rebounded greatly over the past year, SINO BIOPHARM occupied a particularly advantageous position on the back of its enhanced innovation capabilities, its global layout, and improved capital market sentiment, Guotai Junan stressed. As one of China's largest and most well-developed drug makers, SINO BIOPHARM's scale, financing capability, and commercial infrastructure enable it to acquire promising local biotech firms and accelerate the late-stage development and commercialization of assets. AAStocks Financial News |
|